McDermott and Bull executive Search
 

Other News

SOFIA™ Plus Aspiration Catheter

Terumo Neuro Announces Publication of RESTORE Registry Results in the Journal of NeuroInterventional Surgery

SOFIA™ Plus Aspiration Catheter

SOFIA™ Plus Aspiration Catheter

Aliso Viejo, CA, Nov. 17, 2026 (GLOBE NEWSWIRE) — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the publication of results from the RESTORE (REal-World Analyses of Stroke-Thrombus Occlusion REtrieval) registry in the Journal of NeuroInterventional Surgery (JNIS).    RESTORE was a prospective observational registry designed to describe procedural, functional, imaging, and safety outcomes associated with physician-directed mechanical thrombectomy procedures in real-world clinical practice. Devices used as first-line treatment in the observed procedures included the SOFIA™ family of catheters*, and the ERIC™ Retrieval Device, alone or in combination.   Reported RESTORE Outcomes  Among the 688 patients included in the published analysis, the authors reported:  93.0% final successful reperfusion, defined as a modified Thrombolysis in Cerebral Infarction score of mTICI ≥2b.  75.4% first-line reperfusion, defined as mTICI ≥2b.  60.8% first-pass successful reperfusion defined as mTICI ≥2b.  52.9% of patients included in the 90-day mRS analysis achieved functional independence, defined as a modified Rankin Scale (mRS) score ≤2.  55.7% of patients with premorbid mRS 0–2 achieved mRS ≤2 at 90 days.  0.6% symptomatic intracranial hemorrhage within 24 hours.  0.4% embolization to new territory.  3.5% device-related serious adverse events.  The publication also reports a median time of 13 minutes from puncture to clot contact and 17 minutes from puncture to successful reperfusion.  Successful navigation was reported in 97.4% of cases.  Angiographic outcomes were independently assessed by a Core Laboratory, and safety outcomes were reviewed and adjudicated by a Clinical Events Committee.  Final reperfusion may reflect additional passes and/or adjunctive or rescue therapy after first-line device use. The publication notes that device-specific crossover or rescue-device data were not available with sufficient granularity to attribute final reperfusion solely to the first-line device.   The full RESTORE study results are available in the Journal of NeuroInterventional Surgery: https://doi.org/10.1136/jnis-2026-025721  Treatment and device-selection decisions were made by treating physicians as part of routine clinical practice and were not assigned by the study protocol. The registry collected data from those procedures for research purposes. The registry enrolled 710 patients between June 2022 and December 2024. Device utilization is reported in the publication.  Because device use was physician-directed and the registry did not include a randomized or concurrent comparator, these outcomes should not be attributed to any individual device or interpreted as establishing comparative safety or effectiveness.   Study Design and Interpretation  RESTORE was a prospective, multicenter, observational, single-arm registry. Treatment windows, device selection, and procedural strategy were determined by the treating physician according to local standards of care.  RESTORE was an observational registry without randomization or a concurrent comparator arm. Its findings describe observed outcomes and do not establish comparative effectiveness or superiority over other devices or treatment strategies. Participating centers were predominantly high-volume stroke programs with established thrombectomy expertise, which should be considered when interpreting the results.  For More Information  Rebecca Janzon Director, Global Corporate Communications Terumo Neuro Email: Rebecca.janzon@microvention.com  About Terumo Neuro Terumo Neuro is on a mission to preserve and restore brain health by advancing innovation that changes what’s possible in neurovascular care. Working shoulder to shoulder with physicians, customers, and associates, we turn deep clinical insight into proven, refined solutions that elevate practice and improve patient outcomes — the kind of impact that redefines neuro-endovascular treatment. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers a comprehensive portfolio for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, our products are sold in more than 70 countries.  For more information, please visit www.terumoneuro.com.  About Terumo Corporation  Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients and driven by the passion of its associates, Terumo strives to fulfill its Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, Terumo provides a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.  INDICATIONS FOR USE / INTENDED PURPOSE:  *Device Use Reported in the Registry and U.S. Regulatory Status: The SOFIA 5F catheter is cleared in the United States for general intravascular use, including the neuro and peripheral vasculature, and is not indicated as an aspiration catheter. Its use in the registry reflected physician-directed treatment in real-world clinical practice. RESTORE did not assign or direct use of the SOFIA 5F catheter for aspiration and was not designed to establish its safety or effectiveness for that use.  The SOFIA™ Plus Aspiration Catheter (6F) (K173200) with the Gomco 405 Aspiration Pump and MicroVention Tubing Kit is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.   The SOFIA™ Distal Access Catheter (5F) (K142014, K131482) is intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries.   The ERIC™ Retrieval Device (K211120) is indicated to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.   For Healthcare Professional and Intended Uses Only.  Rx Only: Federal (USA) law restricts this device to sale by or on the order of a physician.  SOFIA™ and ERIC™ are trademarks of MicroVention, Inc., Terumo Neuro registered in the United States and other jurisdictions. All brand names and trademarks are registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties.  Refer to Instructions for Use, contraindications, and warnings for additional information.  © 2026 MicroVention, Inc. MM2518 EMEA-US 11/26  Contact Info Rebecca Janzonrebecca.janzon@microvention.com+1 949-685-4391 Attachment SOFIA™ Plus Aspiration Catheter

Perfuze Receives FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Stroke Thrombectomy System

GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a neurovascular medical device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for NeuroSheath™, an 8 French (8F) long sheath specifically designed for neurovascular access. NeuroSheath completes Perfuze’s stroke thrombectomy system, from access through aspiration. It is sized to accommodate Millipede88®, the company’s super-bore aspiration catheter built on patented Corrugated™ technology. NeuroSheath will begin a lim

AliveCor and PulseAI Partner to Bring Advanced Cardiac AI Determinations and Clinical Care Platform to Major Consumer Wearables

FDA-cleared PulseAPI SmartWatch integration adds Premature Ventricular Contraction (PVC) detection to Apple Watch and cuts inconclusive ECG readings by 92%, easing clinical review burden PulseAI’s algorithmic engine also supports ECG rhythm determinations across Samsung, Withings, and Fitbit devices MOUNTAIN VIEW, Calif. & BELFAST, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, and PulseAI, a pioneer in artificial intelligence software for electrocardiogram (ECG) analysis, today announced a strategic partnership to expand clinical-grade cardiac care across mainstream consumer wearables. Leveraging PulseAI’s recent U.S. Food and Drug Administration (FDA) 510(k) clearance for PulseAPI SmartWatch, the collaboration will bring AI rhythm determinations to compatible third-party wearables for users with a KardiaCare subscription via the Kardia App. Most notably, the partnership will offer advanced detection of sinus rhythm with PVCs for Apple Watch customers. This new capability will seamlessly help convert personal wearable data into actionable clinical consultations and specialist overreads, helping close a long-standing gap in consumer wearable diagnostics. “Consumer wearables have successfully fostered personal wellness, but the real breakthrough lies in turning daily tracking into clinically actionable data,” said Priya Abani, CEO of AliveCor. “Heart disease remains the leading global health challenge, and by democratizing access to medical-grade insights and cardiovascular specialists at scale, we can detect conditions earlier, improve outcomes, and save more lives.” “We are excited to announce our first partnership for our AI ECG technology,” said Dr Alan Kennedy, CEO of PulseAI. “Our mission is to make advanced ECG analysis accessible to as many patients as possible. Partnering with AliveCor brings us closer to that goal by connecting the wearable devices people already use with meaningful heart rhythm insights and clinical care.” Clinical-Grade AI for Leading WearablesThe PulseAPI SmartWatch platform acts as an intelligent software library that processes and analyzes Lead I data from compatible wearable devices. Under the FDA clearance, the algorithms deliver automated noise filtering, heart rate measurement, and targeted rhythm classification: Advanced Capabilities for Apple Watch Users: When processing Lead I data from compatible Apple Watch hardware, the platform delivers rhythm analysis for sinus rhythm, atrial fibrillation (AFib), bradycardia, and tachycardia. Critically, it provides beat-by-beat QRS detection to identify normal sinus rhythm versus sinus rhythm with PVCs, classifies individual beats as sinus rhythm with PVC or non-PVC.Broad Consumer Ecosystem Support: PulseAI’s FDA-cleared algorithmic engine supports ECG rhythm determinations (detecting sinus rhythm, AFib, noisy recordings, and average beat calculation) across leading consumer wearables and monitors, including Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch. While consumer wearables have traditionally alerted users to basic rhythm abnormalities, this partnership transforms isolated data into meaningful context for healthcare providers. In Apple Watch, beyond expanding rhythm classifications, the technology directly tackles one of the largest bottlenecks in digital cardiology: the administrative and clinical burden created by inconclusive ECGs, which often trigger manual reviews, repeat recordings, and unnecessary follow-ups. In a prospective study of 296 participants published in Heart Rhythm, PulseAI’s algorithm improved AFib detection sensitivity while delivering a 92% reduction in inconclusive interpretations compared to the Apple Watch’s native algorithm—enabling clinical teams to manage higher recording volumes with existing resources. Advanced determinations from the AliveCor and PulseAi partnership will be available on select, compatible third-party devices including Apple Watch, Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch in the first half of 2027. For more information contact press@alivecor.com. About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the TIME World’s Top HealthTech Companies list for the second consecutive year in 2026—recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 400 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. About PulseAI PulseAI, founded in 2020, is based in Belfast, Northern Ireland. The company has developed deep learning algorithms trained on millions of ECGs to deliver clinically validated performance across smartwatches, patches, hospital monitors, and defibrillators. For more information, visit www.pulseai.io and follow us on LinkedIn and X (Twitter). Media Contacts Alivecor Morgan MathisDirector of Corporate Communications, AliveCorpress@alivecor.com Pulse AIAlan KennedyCEO and Founder, PulseAIalan.kennedy@pulseai.io

Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel

– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel. DURHAM, N.C., Nov. 16, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced new results showing that its acellular tissue engineered vessel (ATEV) were observed to have low susceptibility to atherosclerosis in patients over multiple years of implantation. The findings were presented at the 2026 ISVTE-ISACB Joint Meeting in Miami, a leading scientific meeting for vascular tissue engineering that brings together the field’s major academic laboratories and companies. “Atherosclerosis is one of the long-term threats to any vascular graft. Until now there has been no long-term clinical evidence on how bioengineered vessels hold up against it,” said Juan Wang, Ph.D., Principal Scientist at Humacyte, who presented the findings. “Across more than 50 patients, many with significant cardiovascular risk factors, we saw very little evidence of the disease taking hold in the ATEV, even years after implantation. We believe that these results support the long-term durability of the ATEV as a potential option for vascular surgeons to use in the operating room.” Certain conventional vascular grafts, including a patient’s own vessels, synthetic grafts, and animal-derived tissues, are known to carry a risk of atherosclerosis, which can potentially compromise their long-term performance. In the presentation, titled “Long-Term Clinical Evidence of Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Blood Vessels,” Humacyte scientists analyzed ATEV tissue from 52 patients who received the ATEV for arteriovenous (AV) access in hemodialysis or for peripheral artery bypass across five clinical trials. Implant durations ranged from less than one week to more than five years. “Durability is one of the most important questions surgeons ask about any vascular conduit,” added Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. “This data, drawn from patients implanted for as long as five years, suggest that the ATEV’s biology works over time. That matters as we work to bring the ATEV to more patients including, if approved by the FDA, those who need long-term reliable access for hemodialysis.” Despite a high prevalence of atherosclerosis risk factors in the patient population, the research showed: Minimal lipid deposition (an average of only 0.6% of tissue area) and scarce foam cell formation, both of which are indicators of early atherosclerotic plaque development.Inflammatory cells, including macrophages, were largely absent from the ATEV wall.Over 95% of ATEV explants evaluated showed no or only a minor presence of early markers for atherosclerosis, even after more than five years of implantation.Only 4.7% of ATEVs studied showed some atypical fatty streaks and none showed evidence of vulnerable plaques.Consistent with previous findings, the ATEVs were progressively repopulated with the patient’s own smooth muscle and endothelial cells and adaptively remodeled. The researchers attribute the ATEV’s low susceptibility to atherosclerosis to its acellular, biocompatible composition, and low innate proteoglycan content which may support non-inflammatory repopulation by the patient’s own cells and limit the retention of the lipids and lipoproteins that drive plaque formation. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com. Forward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our plans, anticipated timeline and ability to file applications for, and obtain marketing approvals from, the FDA and other regulatory authorities, including the European Medicines Agency, for our ATEVs and product candidates; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding the results of our clinical trials, and regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs and the public perception thereof; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended September 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com Humacyte Media Contact:Rich LuchettePrecision Strategies+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Adagio Medical Reports Third Quarter 2026 Results

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026. Recent Business Highlights: Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held October 9-10 in New York, with topics spanning clinical experience, comp